Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Labeling Rule Returns To OMB

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA's physician labeling rule has been resubmitted to the White House Office of Management & Budget

You may also be interested in...



Physician Labeling Final Rule Targeted For Release In May

FDA expects to release the physician labeling final rule by the end of May, according to HHS' semi-annual "unified agenda" published in the May 16 Federal Register

Physician Labeling Final Rule Targeted For Release In May

FDA expects to release the physician labeling final rule by the end of May, according to HHS' semi-annual "unified agenda" published in the May 16 Federal Register

Physician Labeling Rule Will Get Four "Companion" Guidances From FDA

Guidances will discuss labeling format, adverse reactions, clinical studies and warnings, FDA's Behrman says. Structured product labeling will roll out this fall and should be fully populated by October 2006, she says.

Topics

UsernamePublicRestriction

Register

LL009864

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel